Group 1 - The core viewpoint of the news is that Aopumai's stock price increased by 5.01% to 61.44 CNY per share, with a total market capitalization of 6.976 billion CNY as of the report date [1] - Aopumai Biotechnology Co., Ltd. was established on November 27, 2013, and went public on September 2, 2022. The company primarily engages in cell culture products and services, with revenue composition being 87.34% from products, 12.53% from services, and 0.13% from other sources [1] Group 2 - Among Aopumai's top ten circulating shareholders, one fund from China Europe Fund, the China Europe Medical Health Mixed A (003095), entered the top ten in the second quarter, holding 1.4824 million shares, which is 1.92% of the circulating shares. The estimated floating profit today is approximately 4.3435 million CNY [2] - The China Europe Medical Health Mixed A (003095) fund was established on September 29, 2016, with a latest scale of 15.638 billion CNY. Year-to-date returns are 31.78%, ranking 2963 out of 8173 in its category; the one-year return is 47.69%, ranking 3188 out of 8003; and since inception, the return is 127.43% [2] Group 3 - The fund managers of China Europe Medical Health Mixed A (003095) are Ge Lan and Zhao Lei. As of the report date, Ge Lan has a cumulative tenure of 10 years and 243 days, with a total fund asset size of 39.908 billion CNY, achieving a best fund return of 122.55% and a worst return of -35.13% during the tenure. Zhao Lei has a tenure of 84 days, with a fund asset size of 30.801 billion CNY, achieving a best return of 15.73% and a worst return of 15.53% during the tenure [3]

Group 1 - The core viewpoint of the news is that Haikang Technology's stock has seen a significant increase, with a rise of 5.15% to 55.38 CNY per share, and a total market capitalization of 62.021 billion CNY [1] - Haikang Technology, established on August 26, 2005, and listed on January 17, 2012, specializes in the research, development, production, and sales of chemical pharmaceuticals [1] - The main revenue composition of Haikang Technology includes anesthetic products (39.81%), cooperative product-related income (23.59%), other indications (17.02%), parenteral nutrition (10.32%), antiemetics for tumors (8.15%), and other supplementary income (0.86%) [1] Group 2 - Among the top ten circulating shareholders of Haikang Technology, a fund under China Europe Fund has increased its holdings by 5.3574 million shares, bringing its total to 21.2763 million shares, which accounts for 4.42% of the circulating shares [2] - The China Europe Medical Health Mixed A Fund (003095) has achieved a year-to-date return of 28.95% and a one-year return of 48.76% [2] - The fund manager, Ge Lan, has a tenure of 10 years and 242 days, with a total fund size of 39.908 billion CNY, achieving a best return of 126.87% during her tenure [3]

Core Viewpoint - The article highlights the increasing prominence of female fund managers in the public fund industry, showcasing their performance and contributions to the sector as their representation grows [3][4]. Summary by Sections Female Fund Managers Overview - As of September 9, 2025, there are 3,868 active public fund managers, with 2,831 males (73.19%) and 1,037 females (26.81%) [3]. Performance of Female Fund Managers - The threshold for the top 10 female fund managers with over 10 years of experience this year is a return of 29.65% [4]. - Among these top performers, two managers from Ping An Fund achieved the highest returns [4]. Top Performing Female Fund Managers - The top female fund manager is Zhou Encong from Ping An Fund, with a return of 90.02% and a management scale exceeding 30 billion yuan [5][6]. - Other notable managers include Ge Lan from China Europe Fund, with a return of 38.66% and a management scale close to 400 billion yuan [6][7]. Fund Management Scale Insights - Among female fund managers, 304 manage over 10 billion yuan, and 72 manage over 50 billion yuan [9]. - The top female fund manager by scale is Cai Kaer from Fu Guo Fund, with a return of 40.99% and a management scale of approximately 588 billion yuan [10][11]. Performance in Active Equity Funds - There are 346 female active equity fund managers, with the top 20 this year having a return threshold of 53.49% [13]. - Zhou Shanshan from交银施罗德基金 leads with a return of 93.45% [14][15]. Investment Focus - Zhou Encong focuses on innovative drugs and believes 2025 will be a pivotal year for the industry [6]. - Ge Lan's top holdings are in the biopharmaceutical sector, indicating a strategic focus on healthcare [7][8]. Conclusion - The article emphasizes the growing influence and success of female fund managers in the public fund industry, reflecting a shift in the investment landscape towards greater gender diversity and performance excellence [3][4].

Group 1 - The core viewpoint of the news is that Guangshengtang has seen a significant increase in its stock price, rising by 5.01% to reach 119.76 yuan per share, with a trading volume of 1.188 billion yuan and a turnover rate of 7.52%, resulting in a total market capitalization of 19.074 billion yuan [1] - Guangshengtang Pharmaceutical Co., Ltd. is primarily engaged in the research, production, and sales of nucleoside antiviral drugs for hepatitis B, with 98.54% of its main business revenue coming from liver and gallbladder disease medications [1] - The company was established on June 28, 2001, and was listed on April 22, 2015, located in Fuzhou, Fujian Province [1] Group 2 - Among the top ten circulating shareholders of Guangshengtang, a fund under China Europe Fund has increased its holdings by 393,100 shares, bringing its total to 1.8447 million shares, which accounts for 1.35% of the circulating shares [2] - The China Europe Medical Health Mixed Fund A (003095) has achieved a year-to-date return of 31.02% and a one-year return of 47.65%, ranking 2473 out of 8174 and 3246 out of 7981 respectively [2] - The fund manager, Ge Lan, has a tenure of 10 years and 230 days, with the fund's total asset size at 39.908 billion yuan and a best return of 128.86% during her tenure [3]

Core Viewpoint - Haoyuan Pharmaceutical experienced a 5.1% increase in stock price, reaching 74.00 CNY per share, with a total market capitalization of 15.695 billion CNY as of September 12 [1] Company Overview - Shanghai Haoyuan Pharmaceutical Co., Ltd. was established on September 30, 2006, and went public on June 8, 2021. The company specializes in the discovery of small molecule drugs, focusing on molecular building blocks and tool compounds, as well as the development and production of active pharmaceutical ingredients (APIs) and intermediates [1] - The main revenue sources for the company include molecular building blocks, tool compounds, and biochemical reagents, accounting for 68.97% of total revenue. Product sales contribute 63.42%, while APIs and intermediates, along with formulations, account for 30.46%. Technical services make up 5.55%, and other sources contribute 0.57% [1] Shareholder Information - Among the top circulating shareholders of Haoyuan Pharmaceutical, a fund under China Europe Fund holds a significant position. The China Europe Healthcare Mixed A Fund (003095) reduced its holdings by 2.7776 million shares in the second quarter, retaining 6.1185 million shares, which represents 2.97% of the circulating shares. The estimated floating profit from this transaction is approximately 21.9653 million CNY [2] - The China Europe Healthcare Mixed A Fund was established on September 29, 2016, with a current scale of 15.638 billion CNY. Year-to-date returns stand at 31.02%, ranking 2473 out of 8174 in its category, while the one-year return is 47.65%, ranking 3246 out of 7981. Since its inception, the fund has achieved a return of 126.12% [2] Fund Management - The fund manager of China Europe Healthcare Mixed A is Ge Lan, who has been in the position for 10 years and 230 days, overseeing assets totaling 39.908 billion CNY, with the best fund return during her tenure being 126.12% and the worst being -35.13% [3] - Co-manager Zhao Lei has been in the role for 71 days, managing assets of 30.801 billion CNY, with the best return being 17.59% and the worst being 17.42% during his tenure [3]

资料显示，浙江九洲药业股份有限公司位于浙江省台州市椒江区外沙路99号，成立日期1998年7月13 日，上市日期2014年10月10日，公司主营业务涉及化学原料药及医药中间体的研发、生产与销售。主营 业务收入构成为：新药定制研发和生产服务(CDMO)79.81%，特色原料药及中间体18.22%，其他 1.96%。 9月1日，九洲药业涨5.14%，截至发稿，报19.02元/股，成交5.94亿元，换手率3.61%，总市值169.17亿 元。 截至发稿，葛兰累计任职时间10年219天，现任基金资产总规模399.08亿元，任职期间最佳基金回报 125.88%， 任职期间最差基金回报-35.13%。 赵磊累计任职时间60天，现任基金资产总规模308.01亿元，任职期间最佳基金回报13.75%， 任职期间 最差基金回报13.59%。 从九洲药业十大流通股东角度 数据显示，中欧基金旗下1只基金位居九洲药业十大流通股东。中欧医疗健康混合A（003095）二季度 减持438.84万股，持有股数1342.63万股，占流通股的比例为1.51%。根据测算，今日浮盈赚取约1248.65 万元。 中欧医疗健康混合A（003095）成立日期 ...

Group 1 - The core viewpoint of the news is that Shouyao Holdings has seen a significant increase in its stock price, rising by 5.18% to reach 48.50 CNY per share, with a total market capitalization of 7.213 billion CNY [1] - Shouyao Holdings, established on April 19, 2016, and listed on March 23, 2022, specializes in the research and development of small molecule anti-tumor drugs, with 100% of its revenue coming from technology development and services [1] Group 2 - Among the top circulating shareholders of Shouyao Holdings, a fund under China Europe Fund, specifically the China Europe Medical Health Mixed A (003095), has entered the top ten shareholders, holding 1.1728 million shares, which accounts for 1.83% of the circulating shares [2] - The China Europe Medical Health Mixed A fund, established on September 29, 2016, has a current scale of 15.638 billion CNY and has achieved a year-to-date return of 28.82%, ranking 2520 out of 8254 in its category [2] Group 3 - The fund managers of China Europe Medical Health Mixed A are Ge Lan and Zhao Lei, with Ge Lan having a tenure of 10 years and 219 days, managing assets totaling 39.908 billion CNY, and achieving a best fund return of 125.88% during her tenure [3] - Zhao Lei has a tenure of 60 days, managing assets of 30.801 billion CNY, with a best fund return of 13.75% during his short tenure [3]

Group 1 - The core viewpoint of the news is that Shenzhou Cell's stock has increased by 5.2%, reaching a price of 66.80 yuan per share, with a total market capitalization of 29.748 billion yuan [1] - Shenzhou Cell, established on April 23, 2007, and listed on June 22, 2020, focuses on the research and commercialization of biopharmaceutical products for various diseases, including malignant tumors and autoimmune diseases [1] - The company's main business revenue is entirely derived from product sales, accounting for 100% of its income [1] Group 2 - Among the top circulating shareholders of Shenzhou Cell, a fund under China Europe Fund, specifically the China Europe Medical Health Mixed A (003095), has entered the top ten shareholders, holding 2.3579 million shares, which is 0.53% of the circulating shares [2] - The China Europe Medical Health Mixed A fund has achieved a year-to-date return of 28.82% and a one-year return of 43.11%, ranking 2520 out of 8254 and 3274 out of 8037 respectively [2] Group 3 - The fund manager of China Europe Medical Health Mixed A is Ge Lan, who has a tenure of 10 years and 219 days, with the fund's total asset size at 39.908 billion yuan and a best return of 125.88% during her tenure [3] - Another fund manager, Zhao Lei, has a tenure of 60 days, managing assets worth 30.801 billion yuan, with a best return of 13.75% during his short tenure [3]

Group 1 - Boten Pharmaceutical Technology Co., Ltd. (stock code: 300363) provides comprehensive services for small molecule drugs, peptides, oligonucleotide drugs, proteins, conjugated drugs, and cell and gene therapies throughout the drug lifecycle, covering locations in China and several countries in Europe and the US [1] - The company has experienced a decline in stock price, with a cumulative drop of -3.44% over four consecutive trading days as of August 21 [1] - In the second quarter of this year, China Europe Fund's China Europe Medical Health Mixed A Fund entered the top ten shareholders of Boten Pharmaceutical, marking a new investment [1] Group 2 - The China Europe Medical Health Mixed A Fund has achieved a year-to-date return of 26.29%, ranking 1357 out of 4492 in its category [1] - The fund is managed by Guo Lan and Zhao Lei, both of whom have extensive backgrounds in biomedical engineering and finance [2][5] - Guo Lan has been with China Europe Fund since October 2014 and has managed multiple funds, while Zhao Lei joined in May 2021 and currently serves as the fund manager and head of the equity research team [4][5]

Group 1 - Aoscicon has experienced a decline for four consecutive trading days, with a cumulative drop of -5.20% [1] - Beijing Aoscicon Pharmaceutical Co., Ltd. was established in 2003 and originated from one of the earliest private new drug research institutions in Jiangsu Province, Nanjing Haiguang Applied Chemistry Research Institute [1] Group 2 - The financial report indicates that the China Europe Fund's China Europe Medical Health Mixed A has entered the top ten shareholders of Aoscicon, marking a new entry in the second quarter of this year [2] - The fund has achieved a year-to-date return of 25.26%, ranking 1433 out of a total of 4493 in its category [2] Group 3 - The fund managers of China Europe Medical Health Mixed A are Ge Lan and Zhao Lei, with Ge Lan holding a Ph.D. in Biomedical Engineering from Northwestern University in the United States [5][6] - Ge Lan has been with China Europe Fund since October 2014 and has managed several funds, currently serving as the manager of China Europe Medical Health Mixed Fund since September 29, 2016 [5][6] Group 4 - Zhao Lei, another fund manager, has a master's degree and has previously worked as a researcher and co-chief analyst in the pharmaceutical and biotechnology sector [7] - Zhao Lei joined China Europe Fund in May 2021 and is currently the manager of China Europe Medical Health Mixed A and C funds, with a recent performance of 12.97% and 13.09% respectively since July 4, 2025 [7] Group 5 - China Europe Fund Management Co., Ltd. was established in July 2006, with a current structure of 25 shareholders, including significant stakes held by WP Asia Pacific Asset Management LLC and Guodu Securities Co., Ltd. [7]